Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping
L Binkhorst, RHJ Mathijssen, A Jager… - Cancer treatment …, 2015 - Elsevier
Clinical response to tamoxifen varies widely among women treated with this drug for
hormone receptor-positive breast cancer. The principal active metabolite–endoxifen–is …
hormone receptor-positive breast cancer. The principal active metabolite–endoxifen–is …
Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy
Tamoxifen reduces the rate of breast cancer recurrence by approximately a half. Tamoxifen
is metabolized to more active metabolites by enzymes encoded by polymorphic genes …
is metabolized to more active metabolites by enzymes encoded by polymorphic genes …
Acidification of the lysosome-like vacuole and the vacuolar H+-ATPase are deficient in two yeast mutants that fail to sort vacuolar proteins.
JH Rothman, CT Yamashiro, CK Raymond… - The Journal of cell …, 1989 - rupress.org
Organelle acidification plays a demonstrable role in intracellular protein processing,
transport, and sorting in animal cells. We investigated the relationship between acidification …
transport, and sorting in animal cells. We investigated the relationship between acidification …
CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
Background Adjuvant tamoxifen therapy is effective for postmenopausal women with
endocrine-responsive breast cancer. Cytochrome P450 2D6 (CYP2D6) enzyme metabolizes …
endocrine-responsive breast cancer. Cytochrome P450 2D6 (CYP2D6) enzyme metabolizes …
CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
Background Adjuvant tamoxifen therapy substantially decreases the risk of recurrence and
mortality in women with hormone (estrogen and/or progesterone) receptor–positive breast …
mortality in women with hormone (estrogen and/or progesterone) receptor–positive breast …
Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis
S Nagalla, JW Chou, MC Willingham, J Ruiz… - Genome biology, 2013 - Springer
Background Gene expression signatures indicative of tumor proliferative capacity and tumor-
immune cell interactions have emerged as principal biology-driven predictors of breast …
immune cell interactions have emerged as principal biology-driven predictors of breast …
CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8
Purpose: Controversy exists about CYP2D6 genotype and tamoxifen efficacy. Experimental
Design: A matched case–control study was conducted using the Austrian Breast and …
Design: A matched case–control study was conducted using the Austrian Breast and …
Effects of pharmacogenetics on the pharmacokinetics and pharmacodynamics of tamoxifen
The antiestrogenic drug tamoxifen is widely used in the treatment of estrogen receptor-α-
positive breast cancer and substantially decreases recurrence and mortality rates. However …
positive breast cancer and substantially decreases recurrence and mortality rates. However …
A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients
J Drewe, KA Bucher, C Zahner - Springerplus, 2015 - Springer
The cardinal climacteric symptoms of hot flushes and night sweats affect 24-93% of all
women during the physiological transition from reproductive to post-reproductive life …
women during the physiological transition from reproductive to post-reproductive life …
Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract
Different antidepressant drugs are currently used for the treatment of depression in cancer
patients, such as second-generation antidepressants and, recently, the extracts of …
patients, such as second-generation antidepressants and, recently, the extracts of …